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Abstract
We conducted high dimensional propensity score-adjusted cohort studies to examine whether 
thiazolidinedione use with a statin or fibrate was associated with an increased risk of severe 
hypoglycemia. We found that concomitant therapy with a thiazolidinedione + fibrate was 
associated with a generally delayed increased risk of severe hypoglycemia.
Keywords
cohort studies; comparative effectiveness research; diabetes mellitus; drug interactions; 
hypoglycemia; hypolipidemic agents; Medicaid; pharmacoepidemiology; propensity score; 
thiazolidinediones
1. INTRODUCTION
Dyslipidemia is a major, yet modifiable, risk factor for cardiovascular disease. While 
glycemic control improves the lipid profile of persons with diabetes, treatment with 
antihyperlipidemics is often indicated. Co-prescribing of antidiabetic and antihyperlipidemic 
agents, though, may not be without risks. In particular, thiazolidinediones (TZDs)—
peroxisome proliferator-activated receptor (PPAR) γ agonists which increase insulin 
sensitivity—are metabolized primarily by hepatic cytochrome P450 (CYP) 2C8.1 This 
isozyme can be inhibited by some antihyperlipidemics, most notably fibrates,2 leading to 
higher concentrations of TZDs. In addition, the PPAR α activity of fibrates may itself have 
effects on glucose homeostasis.3 Some statins may also affect glucose metabolism.4 These 
mechanisms might result in enhanced glucose lowering effects in concomitant users of 
TZDs and certain antihyperlipidemics. While these effects may be desirable for some 
patients, drug interactions might also increase the risk of severe hypoglycemia—a major 
clinical and public health problem. We therefore examined severe hypoglycemia risk among 
concomitant users of TZDs and antihyperlipidemics.
2. METHODS
We conducted two high-dimensional propensity score-adjusted cohort studies of adult users 
of pioglitazone and rosiglitazone, respectively, using Medicaid data from five large states. 
Each cohort consisted exclusively of person-time concomitantly-exposed to the TZD plus 
one of eight antihyperlipidemics: atorvastatin; fenofibrate; fluvastatin; gemfibrozil; 
lovastatin; pravastatin; rosuvastatin; or simvastatin. The day on which the subject was first 
co-exposed served as the cohort entry date. Exposure was defined by the antihyperlipidemic 
active upon cohort entry. The primary outcome was a validated diagnosis-based algorithm 
Leonard et al. Page 2
Diabetes Res Clin Pract. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
for severe hypoglycemia within 30 days of cohort entry. Please see Supplemental Materials 
for details on: the data source; defining the study cohorts; exposure, covariate, and outcome 
ascertainment; and statistical analyses.
3. RESULTS
Pioglitazone
Characteristics of pioglitazone users are presented in Table 1. Unadjusted and adjusted 
hazard ratios (HRs) for severe hypoglycemia within 30 days are presented in Table 2 and 
Fig. 1, respectively. Unadjusted and adjusted HRs for severe hypoglycemia within 180 days 
are presented in Table 2. Time-specific association measures for concomitant use of 
pioglitazone and fibrates are presented in Fig. 2. No time-course effects were evident for 
concomitant use with statins. See Supplemental Materials for results from sensitivity 
analyses.
Rosiglitazone
See Supplemental Material.
4. DISCUSSION
We examined potential drug-drug interactions between TZDs and antihyperlipidemics. 
While we found no increased risk of severe hypoglycemia during the first month of 
concomitant pioglitazone and antihyperlipidemic therapy, the risk was elevated and 
increased monotonically with time during later months of concomitant therapy with a 
fibrate. Pioglitazone+fenofibrate was associated with an increased risk of severe 
hypoglycemia as much as 2.3-fold during 60–180d post-initiation of concomitant therapy, 
and pioglitazone+gemfibrozil as much as 2.6-fold during 30–180d. For rosiglitazone, we 
found no increased risk of severe hypoglycemia during the first 30d of concomitant use with 
a statin, but use of rosiglitazone+gemfibrozil was associated with a 1.6-fold increased risk. 
Subsequently, the risk of severe hypoglycemia peaked during 30–59d—1.8-fold for 
rosiglitazone+fenofibrate and 2.5-fold for rosiglitazone+gemfibrozil—and returned to the 
null by 180d.
This is first pharmacoepidemiologic investigation of these potential drug interactions. The 
presumptive mechanism underlying prior pharmacokinetic- and laboratory science-based 
work was that fibrates inhibited CYP2C8, the major metabolic pathway for TZDs. Yet, even 
if inhibition by fibrates significantly raises serum concentrations of TZDs, it is not generally 
thought that TZDs cause severe hypoglycemia.5 However, we found that severe 
hypoglycemia occurs at a rate of ~2.5 per 100 p-y among TZD users even in the absence of 
concomitant insulin or sulfonylureas. Further, Bron et al reported that TZDs are associated 
with a small but significant increased risk of moderate or severe hypoglycemia, especially 
within the first year of therapy.6 This raises the possibility that TZDs, while clearly less 
associated with hypoglycemia than insulin or sulfonylureas, may cause severe hypoglycemia 
in certain circumstances. That being said, the mechanism seems more complex than elevated 
TZD serum concentrations caused by CYP2C8 inhibition. Arguments against a lone, major 
role for CYP2C8 inhibition include: some statins also inhibit CYP2C8,7 yet we did not find 
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elevated HRs for statins; and the inhibition and inactivation of CYP enzymes occurs 
rapidly,8 yet we generally found delayed rather than rapid-onset increases in the risk of 
severe hypoglycemia. This latter point could also be explained by the delayed onset of action 
of TZDs, whose effects may peak at one month.9,10
A more plausible explanation for our findings may be driven by expected actions of fibrates. 
The PPAR α agonist effects of fibrates beneficially impact lipid and lipoprotein metabolism. 
Lipid and glucose homeostasis is interrelated11 and lowering free fatty acids ameliorates 
insulin resistance12 and13 via protection of pancreatic islets14. Alternatively, or in addition, 
fibrates may induce fatty acid-binding protein and stimulate β-oxidation in skeletal 
muscles15. Regardless of potential mechanism, improvements in insulin resistance and 
glycemic control have been reported in users of gemfibrozil16 and fenofibrate13 and 17. 
Further, some fibrates also act at PPAR γ18, the site of action of TZDs. Of further interest are 
differences between pioglitazone and rosiglitazone in the time-course of their interaction 
with fibrates—the former increasing monotonically with time (Fig. 2) and the latter having 
an inverted U-shape (Supplementary Figure 2). The sustained risk of severe hypoglycemia 
observed with pioglitazone + gemfibrozil or fenofibrate may be mediated by pioglitazone's 
more favorable effect on lipids compared to rosiglitazone19; pioglitazone significantly 
reduces fatty acids and triglycerides20. As discussed above, this may lead to less insulin 
resistance. The lack of a sustained risk with rosiglitazone + fibrate may be due to a 
sufficiently weaker interaction to which patients can develop compensatory behaviors or 
endocrine adaptations over time. Future studies should investigate the relative contributions 
of these and other potential mechanisms.
See Supplemental Material for a discussion of this work’s strengths and limitations.
5. CONCLUSION
We found that concomitant therapy with a TZD and fibrate is associated with an increased 
risk of severe hypoglycemia. The mechanism underlying this apparent drug-drug interaction 
needs further elucidation, but may involve fibrates ‘impact on glucose (i.e., a 
pharmacodynamic interaction mediated by PPAR α ± γ effects). Clinicians should be attuned 
to both immediate- and delayed-onset hypoglycemia in their patients on this drug 
combination.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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HIGHLIGHTS
• Concomitant use of an antidiabetic thiazolidinedione (i.e., pioglitazone or 
rosiglitazone) with a fibrate (i.e., gemfibrozil or fenofibrate) was associated with 
an approximate 1.5- to 2.5-fold increased risk of severe hypoglycemia.
• This increased risk generally manifested after the first month of concomitant 
use.
• Severe hypoglycemia occurs in some patients receiving a thiazolidinedione, 
even without concomitant exposure to insulin or a sulfonylurea.
• The apparent drug-drug interaction between thiazolidinediones and fibrates is an 
underappreciated cause of severe hypoglycemia—a health outcome of interest 
that is the largest barrier to glycemic control, reduces quality of life, and can 
lead to major adverse cardiovascular events, dementia or death.
• Clinicians should be attuned to both immediate- and delayed-onset 
hypoglycemia in their patients treated concomitantly with thiazolidinediones 
and fibrates.
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Figure 1. 
Adjusted hazard ratios (HRs) for the rate of severe hypoglycemia within 30 days of cohort 
entry among pioglitazone users, by antihyperlipidemic of interest (vs. pravastatin)
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Figure 2. 
Adjusted hazard ratios (HRs) for the rate of severe hypoglycemia within 180 days of cohort 
entry among pioglitazone users, by fibrate of interest (vs. pravastatin), by time window
Leonard et al. Page 9
Diabetes Res Clin Pract. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leonard et al. Page 10
Ta
bl
e 
1
Ch
ar
ac
te
ris
tic
s o
f p
io
gl
ita
zo
ne
 u
se
rs
, b
y 
an
tih
yp
er
lip
id
em
ic
 ex
po
su
re
 g
ro
up
A
na
ly
se
s e
xa
m
in
in
g 
30
-d
ay
 ti
m
e
pe
ri
od
 p
os
t-c
oh
or
t e
nt
ry
St
at
in
s
Fi
br
at
es
pr
av
a
st
at
in
a
to
rv
a
st
at
in
flu
va
st
at
in
lo
v
a
st
at
in
ro
su
v
a
st
at
in
sim
va
st
at
in
fe
no
fib
ra
te
ge
m
fib
ro
zi
l
N
s (
un
les
s o
th
er
wi
se 
no
ted
)
U
se
rs
, c
on
co
m
ita
nt
 w
ith
 p
io
gl
ita
zo
ne
21
,0
66
10
9,
37
1
4,
75
7
15
,8
18
13
,0
14
69
,8
47
10
,9
69
11
,5
31
Pe
rs
on
-y
ea
rs
 o
f f
ol
lo
w
-u
p
1,
70
9
8,
90
9
38
5
1,
28
2
1,
04
8
5,
66
2
82
9
89
1
Se
v
er
e 
hy
po
gl
yc
em
ia
 ev
en
ts
 w
ith
in
 3
0 
da
ys
 o
f c
oh
or
t e
nt
ry
12
4
59
5
20
68
43
40
8
53
65
Cu
m
ul
at
iv
e 
in
ci
de
nc
e 
of
 se
v
er
e 
hy
po
gl
yc
em
ia
 w
ith
in
 3
0 
da
ys
 o
f c
oh
or
t e
nt
ry
 (9
5%
 C
I)
0.
59
%
 (0
.49
–0
.70
)
0.
54
%
 (0
.50
–0
.59
)
0.
42
%
 (0
.26
–0
.65
)
0.
43
%
 (0
.33
–0
.54
)
0.
33
%
 (0
.24
–0
.44
)
0.
58
%
 (0
.53
–0
.64
)
0.
48
%
 (0
.36
–0
.63
)
0.
56
%
 (0
.44
–0
.72
)
D
em
og
ra
ph
ic
s
G
ro
u
p
%
 (u
nle
ss 
oth
erw
ise
 no
ted
)
A
ge
 in
 y
ea
rs
 a
t c
oh
or
t e
nt
ry
 (c
on
tin
uo
us
)
M
ed
ia
n 
(Q
1-Q
3)
66
.4
 (5
6.0
–7
4.1
)
64
.7
 (5
4.3
–7
3.0
)
63
.1
 (5
2.4
–7
2.5
)
63
.3
 (5
1.0
–7
2.8
)
65
.3
 (5
4.5
–7
3.1
)
65
.5
 (5
5.1
–7
3.6
)
59
.8
 (4
8.5
–7
0.4
)
57
.8
 (4
7.7
–6
8.9
)
Se
x
fe
m
al
e
66
.5
65
.0
68
.4
64
.2
64
.4
64
.8
56
.8
53
.7
R
ac
e
w
hi
te
35
.1
37
.1
35
.1
28
.9
32
.8
36
.2
49
.8
40
.0
bl
ac
k
13
.6
13
.9
14
.0
12
.1
11
.6
15
.0
6.
5
7.
0
o
th
er
 / 
un
kn
ow
n
51
.3
49
.0
51
.0
59
.0
55
.5
48
.8
43
.7
52
.9
St
at
e 
of
 re
sid
en
ce
CA
58
.3
52
.0
59
.7
69
.6
40
.4
41
.2
41
.6
61
.5
FL
8.
4
5.
9
10
.0
8.
0
19
.4
11
.1
12
.5
8.
2
N
Y
21
.8
27
.8
16
.4
12
.2
33
.3
32
.8
26
.5
18
.9
O
H
5.
6
9.
1
6.
3
4.
5
4.
0
8.
5
12
.4
6.
9
PA
5.
9
5.
3
7.
7
5.
8
2.
8
6.
4
7.
0
4.
5
Ca
le
nd
ar
 y
ea
r o
f c
oh
or
t e
nt
ry
20
00
–2
00
3
54
.7
36
.5
52
.5
10
.7
1.
4
22
.3
28
.0
39
.8
20
04
10
.3
11
.0
13
.2
9.
0
9.
9
6.
3
9.
1
10
.3
20
05
10
.1
13
.8
13
.5
13
.3
16
.5
11
.0
14
.3
12
.3
20
06
8.
8
13
.8
11
.0
25
.3
23
.3
14
.9
16
.0
11
.7
20
07
9.
0
16
.4
7.
3
26
.6
30
.6
26
.1
19
.1
15
.0
20
08
7.
0
8.
5
2.
5
15
.1
18
.4
19
.3
13
.5
11
.0
M
ed
ic
ar
e 
en
ro
lle
d
Ye
s
66
.2
62
.2
58
.5
60
.5
61
.5
64
.5
59
.6
52
.8
N
ur
sin
g 
ho
m
e 
re
sid
en
ce
, e
v
er
 d
ur
in
g 
ba
se
lin
e
Ye
s
4.
7
6.
6
4.
0
5.
5
2.
8
6.
8
5.
1
5.
6
H
ea
lth
ca
re
 u
til
iz
at
io
n 
co
v
a
ri
at
es
, i
n 
ba
se
lin
e 
pe
ri
od
*
G
ro
u
p
m
ea
su
re
s 
o
f c
en
tra
l t
en
de
nc
y
Diabetes Res Clin Pract. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leonard et al. Page 11
A
na
ly
se
s e
xa
m
in
in
g 
30
-d
ay
 ti
m
e
pe
ri
od
 p
os
t-c
oh
or
t e
nt
ry
St
at
in
s
Fi
br
at
es
pr
av
a
st
at
in
a
to
rv
a
st
at
in
flu
va
st
at
in
lo
v
a
st
at
in
ro
su
v
a
st
at
in
sim
va
st
at
in
fe
no
fib
ra
te
ge
m
fib
ro
zi
l
N
s (
un
les
s o
th
er
wi
se 
no
ted
)
# 
pr
es
cr
ip
tio
ns
 d
isp
en
se
d
M
ed
ia
n 
(Q
1-Q
3)
57
.0
 (3
3.0
–9
0.0
)
58
.0
 (3
3.0
–9
3.0
)
52
.0
 (2
8.0
–8
3.0
)
44
.0
 (2
2.0
–7
6.0
)
58
.0
 (3
2.0
–9
3.0
)
58
.0
 (3
1.0
–9
4.0
)
65
.0
 (3
6.0
–1
06
)
57
.0
 (3
1.0
–9
2.0
)
# 
un
iq
ue
 d
ru
gs
 d
isp
en
se
d
M
ed
ia
n 
(Q
1-Q
3)
15
.0
 (1
0.0
–2
2.0
)
15
.0
 (9
.0–
21
.0)
13
.0
 (8
.0–
20
.0)
12
.0
 (7
.0–
18
.0)
15
.0
 (9
.0–
22
.0)
14
.0
 (9
.0–
21
.0)
16
.0
 (1
0.0
–2
3.0
)
14
.0
 (9
.0–
21
.0)
# 
ou
tp
at
ie
nt
 d
ia
gn
os
is 
co
de
s
M
ed
ia
n 
(Q
1-Q
3)
47
.0
 (2
3.0
–9
0.0
)
47
.0
 (2
3.0
–9
5.0
)
36
.0
 (1
6.0
–7
1.0
)
27
.0
 (1
0.0
–6
1.0
)
43
.0
 (2
0.0
–8
9.0
)
44
.0
 (1
9.0
–9
5.0
)
50
.0
 (2
4.0
–9
8.0
)
40
.0
 (1
8.0
–8
2.0
)
# 
un
iq
ue
 o
ut
pa
tie
nt
 d
ia
gn
os
is 
co
de
s
M
ed
ia
n 
(Q
1-Q
3)
17
.0
 (1
0.0
–2
6.0
)
16
.0
 (9
.0–
26
.0)
13
.0
 (7
.0–
23
.0)
11
.0
 (5
.0–
20
.0)
15
.0
 (9
.0–
25
.0)
15
.0
 (8
.0–
26
.0)
17
.0
 (1
0.0
–2
7.0
)
14
.0
 (8
.0–
23
.0)
# 
ou
tp
at
ie
nt
 C
PT
-
4 
/ H
CP
CS
 p
ro
ce
du
re
 c
od
es
M
ed
ia
n 
(Q
1-Q
3)
55
.0
 (2
8.0
–1
03
)
55
.0
 (2
7.0
–1
04
)
45
.0
 (2
2.0
–8
5.0
)
38
.0
 (1
6.0
–7
5.0
)
53
.0
 (2
6.0
–1
02
)
51
.0
 (2
2.0
–1
03
)
58
.0
 (3
0.0
–1
07
)
48
.0
 (2
4.0
–9
3.0
)
# 
un
iq
ue
 o
ut
pa
tie
nt
 C
PT
-
4 
/ H
CP
CS
 p
ro
ce
du
re
 c
od
es
M
ed
ia
n 
(Q
1-Q
3)
30
.0
 (1
7.0
–4
8.0
)
29
.0
 (1
6.0
–4
9.0
)
26
.0
 (1
4.0
–4
1.0
)
22
.0
 (1
0.0
–3
9.0
)
29
.0
 (1
6.0
–4
8.0
)
28
.0
 (1
4.0
–4
8.0
)
31
.0
 (1
8.0
–4
9.0
)
27
.0
 (1
5.0
–4
5.0
)
O
th
er
 in
v
es
tig
at
or
 p
re
- 
de
fin
ed
 c
ov
a
ri
at
es
, i
n 
ba
se
lin
e 
pe
ri
od
G
ro
u
p
%
Pr
io
r s
ev
er
e 
hy
po
gl
yc
em
ia
Ye
s
3.
4
3.
4
2.
7
2.
4
2.
0
3.
5
2.
7
3.
4
A
lp
ha
-g
lu
co
sid
as
e 
in
hi
bi
to
r e
x
po
su
re
Ye
s
2.
5
2.
2
2.
5
1.
7
1.
6
1.
9
1.
9
2.
1
D
PP
-4
 in
hi
bi
to
r e
x
po
su
re
Ye
s
0.
7
1.
1
0.
4
1.
1
3.
2
2.
1
1.
9
0.
7
G
LP
-1
 in
hi
bi
to
r e
x
po
su
re
Ye
s
0.
3
0.
5
*
*
0.
7
1.
5
0.
9
1.
1
0.
4
In
su
lin
 ex
po
su
re
Ye
s
25
.4
26
.1
23
.1
20
.4
19
.1
24
.7
23
.5
25
.3
M
eg
lit
in
id
e 
ex
po
su
re
Ye
s
6.
7
5.
3
5.
0
3.
0
5.
4
4.
7
6.
6
4.
5
M
et
fo
rm
in
 ex
po
su
re
Ye
s
59
.4
60
.9
58
.8
65
.8
60
.7
61
.1
59
.6
65
.6
Su
lfo
ny
lu
re
a 
ex
po
su
re
: g
lip
iz
id
e
Ye
s
22
.7
23
.9
25
.5
26
.6
18
.9
22
.8
19
.3
26
.0
Su
lfo
ny
lu
re
a 
ex
po
su
re
: g
ly
bu
rid
e
Ye
s
29
.4
27
.0
29
.2
28
.0
22
.8
27
.0
23
.5
30
.2
Su
lfo
ny
lu
re
a 
ex
po
su
re
: o
th
er
 a
ge
nt
Ye
s
11
.4
11
.4
9.
5
10
.8
12
.7
10
.8
13
.5
10
.1
CI
 =
 c
on
fid
en
ce
 in
te
rv
al
; C
PT
-
4 
= 
Cu
rre
nt
 P
ro
ce
du
ra
l T
er
m
in
ol
og
y-
4;
 D
PP
-4
 =
 d
ip
ep
tid
yl
 p
ep
tid
as
e-
4;
 G
LP
-1
 =
 g
lu
ca
go
n-
lik
e 
pe
pt
id
e-
1;
 H
CP
CS
 =
 H
ea
lth
ca
re
 C
om
m
on
 P
ro
ce
du
re
 C
od
in
g 
Sy
ste
m
; Q
 = 
qu
art
ile
*
th
e 
fo
llo
w
in
g 
he
al
th
ca
re
 u
til
iz
at
io
n 
co
v
ar
ia
te
s w
er
e 
ex
cl
ud
ed
 fr
om
 th
e 
ta
bl
e,
 a
s t
he
 m
ed
ia
n 
va
lu
es
 w
er
e 
ze
ro
: #
 in
pa
tie
nt
 In
te
rn
at
io
na
l C
la
ss
ifi
ca
tio
n 
of
 D
ise
as
es
, 9
th
 
R
ev
isi
on
 (I
CD
-9)
 di
ag
no
sis
 co
de
s; 
# u
niq
ue
 in
pa
tie
nt 
IC
D-
9 d
iag
no
sis
 co
de
s; 
# i
np
ati
en
t I
CD
-9 
pro
ce
du
re 
co
de
s; 
# 
un
iq
ue
 in
pa
tie
nt
 IC
D
-9
 p
ro
ce
du
re
 co
de
s; 
# 
in
pa
tie
nt
 C
PT
-
4/
H
CP
CS
 p
ro
ce
du
re
 c
od
es
; #
 u
ni
qu
e 
in
pa
tie
nt
 C
PT
-
4/
H
CP
CS
 p
ro
ce
du
re
 c
od
es
; #
 o
ut
pa
tie
nt
 IC
D
-9
 p
ro
ce
du
re
 co
de
s; 
# 
un
iq
ue
 o
ut
pa
tie
nt
 IC
D
-9
 p
ro
ce
du
re
 co
de
s; 
# 
ot
he
r s
et
tin
g 
di
ag
no
sis
 co
de
s; 
# 
un
iq
ue
 o
th
er
 
se
tti
ng
 d
ia
gn
os
is 
co
de
s; 
# 
ot
he
r s
et
tin
g 
IC
D
-9
 p
ro
ce
du
re
 co
de
s; 
# 
un
iq
ue
 o
th
er
 se
tti
ng
 IC
D
-9
 p
ro
ce
du
re
 co
de
s
*
*
o
m
itt
ed
 in
 c
om
pl
ia
nc
e 
w
ith
 C
en
te
rs
 fo
r M
ed
ic
ar
e 
&
 M
ed
ic
ai
d 
Se
rv
ic
es
 p
riv
ac
y 
po
lic
y 
(i.
e.,
 un
de
rly
ing
 ce
ll c
ou
nt 
<1
1 p
ers
on
s)
Diabetes Res Clin Pract. Author manuscript; available in PMC 2017 May 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Leonard et al. Page 12
Ta
bl
e 
2
Su
m
m
ar
y 
of
 fi
nd
in
gs
: p
io
gl
ita
zo
ne
 +
 a
nt
ih
yp
er
lip
id
em
ic
 a
nd
 th
e 
ris
k 
of
 se
v
er
e 
hy
po
gl
yc
em
ia
A
na
ly
se
s e
xa
m
in
in
g 
30
-d
ay
 ti
m
e p
er
io
d 
po
st
-c
oh
or
t e
nt
ry
St
at
in
s
Fi
br
at
es
pr
av
a
st
at
in
a
to
rv
a
st
at
in
flu
va
st
at
in
lo
v
a
st
at
in
ro
su
v
a
st
at
in
sim
va
st
at
in
fe
no
fib
ra
te
ge
m
fib
ro
zi
l
Po
in
t e
st
im
at
es
 (9
5%
 C
I) 
fro
m
 p
ri
m
ar
y 
an
al
ys
es
U
na
dju
ste
d H
R
re
fe
re
nc
e
0.
92
 (0
.76
–1
.12
)
0.
72
 (0
.45
–1
.15
)
0.
73
 (0
.54
–0
.98
)
0.
57
 (0
.40
–0
.80
)
0.
99
 (0
.81
–1
.21
)
0.
88
 (0
.64
–1
.21
)
1.
00
 (0
.74
–1
.35
)
A
dju
ste
d H
R 
[se
e F
igu
re 
1]
0.
94
 (0
.77
–1
.14
)
0.
85
 (0
.53
–1
.37
)
0.
99
 (0
.73
–1
.35
)
0.
91
 (0
.63
–1
.30
)
1.
07
 (0
.87
–1
.32
)
1.
08
 (0
.78
–1
.49
)
1.
15
 (0
.85
–1
.56
)
Po
in
t e
sti
m
at
es
 (9
5%
 C
I) 
fro
m 
sen
sit
ivi
ty
 a
na
ly
se
s
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
SU
 u
se
rs
*
re
fe
re
nc
e
1.
17
 (0
.87
–1
.58
)
1.
20
 (0
.62
–2
.31
)
1.
15
 (0
.71
–1
.84
)
1.
05
 (0
.61
–1
.78
)
1.
23
 (0
.90
–1
.69
)
0.
91
 (0
.53
–1
.55
)
1.
23
 (0
.77
–1
.96
)
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
SU
 o
r i
ns
ul
in
 
u
se
rs
*
*
1.
62
 (0
.83
–3
.15
)
2.
09
 (0
.65
–6
.73
)
2.
05
 (0
.84
–5
.03
)
1.
91
 (0
.73
–5
.01
)
1.
64
 (0
.81
–3
.31
)
1.
32
 (0
.47
–3
.68
)
1.
62
 (0
.63
–4
.18
)
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
co
v
ar
ia
te
s f
ro
m
 th
e 
PS
 st
ro
ng
ly
 re
la
te
d 
to
 ex
po
su
re
 b
u
t n
ot
 
o
u
tc
om
e
0.
94
 (0
.77
–1
.14
)
0.
84
 (0
.52
–1
.35
)
1.
00
 (0
.74
–1
.37
)
0.
92
 (0
.64
–1
.31
)
1.
07
 (0
.87
–1
.32
)
1.
07
 (0
.77
–1
.49
)
1.
14
 (0
.84
–1
.55
)
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
m
an
ag
ed
 c
ar
e 
en
ro
lle
es
0.
97
 (0
.77
–1
.22
)
1.
03
 (0
.60
–1
.75
)
1.
25
 (0
.84
–1
.87
)
0.
86
 (0
.56
–1
.31
)
1.
12
 (0
.89
–1
.43
)
1.
08
 (0
.74
–1
.58
)
1.
26
 (0
.89
–1
.79
)
A
na
ly
se
s e
xa
m
in
in
g 
18
0-
da
y 
tim
e p
er
io
d 
po
st
-c
oh
or
t e
nt
ry
Po
in
t e
sti
m
at
es
 (9
5%
 C
I) 
fro
m 
pri
ma
ry 
an
aly
ses
U
na
dju
ste
d H
R
re
fe
re
nc
e
1.
00
 (0
.88
–1
.13
)
0.
88
 (0
.67
–1
.17
)
0.
74
 (0
.61
–0
.89
)
0.
62
 (0
.49
–0
.77
)
1.
01
 (0
.89
–1
.16
)
1.
05
 (0
.86
–1
.29
)
1.
34
 (1
.11
–1
.62
)
A
dju
ste
d H
R
1.
02
 (0
.90
–1
.15
)
1.
03
 (0
.78
–1
.37
)
1.
02
 (0
.83
–1
.25
)
1.
02
 (0
.81
–1
.28
)
1.
11
 (0
.97
–1
.27
)
1.
33
 (1
.08
–1
.63
)
1.
60
 (1
.32
–1
.93
)
Po
in
t e
sti
m
at
es
 (9
5%
 C
I) 
fro
m 
sen
sit
ivi
ty
 a
na
ly
se
s
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
SU
 u
se
rs
*
re
fe
re
nc
e
1.
10
 (0
.91
–1
.34
)
1.
20
 (0
.78
–1
.84
)
0.
98
 (0
.71
–1
.36
)
1.
14
 (0
.80
–1
.62
)
1.
13
 (0
.92
–1
.39
)
1.
05
 (0
.75
–1
.47
)
1.
39
 (1
.03
–1
.88
)
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
SU
 o
r i
ns
ul
in
 
u
se
rs
*
*
1.
20
 (0
.77
–1
.86
)
2.
25
 (1
.07
–4
.76
)
1.
12
 (0
.57
–2
.20
)
1.
30
 (0
.64
–2
.61
)
1.
19
 (0
.74
–1
.90
)
0.
96
 (0
.45
–2
.04
)
1.
52
 (0
.80
–2
.90
)
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
co
v
ar
ia
te
s f
ro
m
 th
e 
PS
 st
ro
ng
ly
 re
la
te
d 
to
 ex
po
su
re
 b
u
t n
ot
 
o
u
tc
om
e
1.
02
 (0
.90
–1
.16
)
1.
03
 (0
.77
–1
.36
)
1.
02
 (0
.83
–1
.24
)
1.
01
 (0
.81
–1
.27
)
1.
11
 (0
.97
–1
.27
)
1.
31
 (1
.07
–1
.61
)
1.
59
 (1
.31
–1
.92
)
A
dju
ste
d H
R,
 ex
cl
ud
in
g 
m
an
ag
ed
 c
ar
e 
en
ro
lle
es
1.
07
 (0
.92
–1
.24
)
1.
11
 (0
.80
–1
.55
)
1.
09
 (0
.83
–1
.43
)
1.
04
 (0
.80
–1
.36
)
1.
15
 (0
.99
–1
.34
)
1.
36
 (1
.07
–1
.72
)
1.
57
 (1
.25
–1
.96
)
CI
 =
 c
on
fid
en
ce
 in
te
rv
al
; H
R 
= 
ha
za
rd
 ra
tio
; P
S 
= 
pr
op
en
sit
y 
sc
or
e;
 S
U
 =
 su
lfo
ny
lu
re
a
B
ol
de
d 
va
lu
es
 m
et
 th
e 
tra
di
tio
na
l t
hr
es
ho
ld
 fo
r s
ta
tis
tic
al
 si
gn
ifi
ca
nc
e
*
if 
co
-e
x
po
se
d 
w
ith
in
 6
0 
da
ys
 p
rio
r t
o 
co
ho
rt 
en
try
 an
d 
ce
ns
or
in
g 
fo
llo
w
-u
p 
tim
e 
if 
su
bs
eq
ue
nt
ly
 ex
po
se
d 
to
 a
 S
U
*
*
if 
co
-e
x
po
se
d 
w
ith
in
 6
0 
da
ys
 p
rio
r t
o 
co
ho
rt 
en
try
 an
d 
ce
ns
or
in
g 
fo
llo
w
-u
p 
tim
e 
if 
su
bs
eq
ue
nt
ly
 ex
po
se
d 
to
 a
 S
U
 o
r i
ns
ul
in
Diabetes Res Clin Pract. Author manuscript; available in PMC 2017 May 01.
